for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

ArQule, Inc.

ARQL.OQ

Latest Trade

9.31USD

Change

0.34(+3.79%)

Volume

605,893

Today's Range

9.15

 - 

9.60

52 Week Range

2.23

 - 

12.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
8.97
Open
9.15
Volume
605,893
3M AVG Volume
41.20
Today's High
9.60
Today's Low
9.15
52 Week High
12.21
52 Week Low
2.23
Shares Out (MIL)
120.26
Market Cap (MIL)
1,078.74
Forward P/E
-24.92
Dividend (Yield %)
--

Next Event

Q3 2019 ArQule Inc Earnings Release

Latest Developments

More

Bleichroeder LP Reports 13.25% Passive Stake In ArQule Inc As Of September 1

Stealth BioTherapeutics Announces Appointment Of Robert Weiskopf As Chief Financial Officer

ArQule Sees FY 2019 Revenue $3.0 Million To $5.0 Million

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About ArQule, Inc.

ArQule, Inc. is a biopharmaceutical company that is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focus on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of approximately four drug candidates, all of which are in targeted patient populations. The Company's product candidates include ARQ 531, Miransertib (ARQ 092), ARQ 751, Miransertib (ARQ 092) and ARQ 751. ARQ 531 is a potent and reversible dual inhibitor of both wild type and C481S-mutant Bruton’s tyrosine kinase (BTK). ARQ 092 is a potent and selective inhibitor of protein kinase B (AKT), a serine/threonine kinase. ARQ 751 is a potent and selective inhibitor of AKT that is in Phase I clinical development for solid tumors harboring AKT, phosphoinositide 3-kinase (PI3K). ARQ 087 is a multi-kinase inhibitor designed to preferentially inhibit the fibroblast.

Industry

Biotechnology & Drugs

Contact Info

1 Wall St Fl 6

+1.781.9940300

https://www.arqule.com/

Executive Leadership

Patrick J. Zenner

Independent Chairman of the Board

Peter S. Lawrence

President, Chief Operating Officer

Paolo Pucci

Chief Executive Officer, Director

Marc Schegerin

Chief Financial Officer

Brian Schwartz

Chief Medical Officer

Key Stats

1.78 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2018

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.330

2017

-0.390

2018

-0.160

2019(E)

-0.359
Price To Earnings (TTM)
--
Price To Sales (TTM)
113.00
Price To Book (MRQ)
6.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
9.23
LT Debt To Equity (MRQ)
6.65
Return on Investment (TTM)
-31.20
Return on Equity (TTM)
-28.20

Latest News

Latest News

BRIEF-Basilea Announces Collaboration To Study Derazantinib And Atezolizumab In Urothelial Cancer

* BASILEA ANNOUNCES COLLABORATION TO STUDY DERAZANTINIB AND ATEZOLIZUMAB (TECENTRIQ®) IN UROTHELIAL CANCER

BRIEF-Arqule Reports Q1 Loss Per Share Of $0.07

* Q1 EARNINGS PER SHARE VIEW $-0.06 -- THOMSON REUTERS I/B/E/S

BRIEF-Arqule And Basilea Enter Into Exclusive License Agreement For Derazantinib

* ARQULE AND BASILEA ENTER INTO EXCLUSIVE LICENSE AGREEMENT FOR DERAZANTINIB IN THE US, EU, JAPAN AND REST OF WORLD EXCLUDING GREATER CHINA

BRIEF-ArQule Reports Q4 Loss Per Share $0.09

* ARQULE REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Roivant Sciences And Arqule Enter Into License Agreement For Derazantinib In China

* ROIVANT SCIENCES AND ARQULE ENTER INTO LICENSE AGREEMENT FOR DERAZANTINIB IN CHINA

BRIEF-ArQule Files For Offering Of Up To 17.1 Million Shares

* ARQULE INC FILES FOR OFFERING OF UP TO 17.1 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING Source text for Eikon: (http://bit.ly/2ivqMQn) Further company coverage:

BRIEF-Arqule reports dosing in registrational trial of FGFR inhibitor

* Arqule announces dosing in a registrational trial of fgfr inhibitor, derazantinib, for treatment of intrahepatic cholangiocarcinoma

BRIEF-Arqule reports Q3 loss per share $0.09

* Q3 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

BRIEF-ArQule announces $9.5 mln private placement of preferred stock

* ArQule announces $9.5 million private placement of preferred stock

BRIEF-Arqule announces $15.7 mln private placement of common stock

* Arqule announces $15.7 million private placement of common stock

BRIEF-Arqule Inc CEO Paolo Pucci​ buys 19,156 shares of co's common stock on Sept 5

* Arqule Inc CEO Paolo Pucci reports purchase of 19,156 shares of co's common stock on Sept 5 at average price of $1.14 per share - SEC filing Source text: (http://bit.ly/2j4eXnk) Further company coverage:

BRIEF-Arqule Q2 loss per share $0.10

* Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

BRIEF-Arqule Q1 loss per share $0.11

* Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

BRIEF-ArQule receives clearance of IND application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

* ArQule receives clearance of investigational new drug application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

* Trial did not meet its primary endpoint of progression free survival (pfs).

BRIEF-Arqule posts Q4 loss per share of $0.10

* Arqule reports fourth quarter and full year 2016 financial results

BRIEF-Daiichi Sankyo and ArQule's carcinoma drug failed in late-stage trial

* Daiichi Sankyo and Arqule announce the completion of the metiv-hcc phase 3 study of tivantinib in second-line treatment of met-overexpressing hepatocellular carcinoma

BRIEF-Arqule Q3 loss $0.08/shr

* Q3 earnings per share view $-0.09 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:

BRIEF-Arqule enters into capital on demand sales agreement with Jonestrading Institutional Services LLC on Oct. 25

* Arqule- On October 25, 2016, co entered into a capital on demand!" sales agreement with Jonestrading Institutional Services LLC - sec filing

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up